FIELD: biotechnology; medicine.
SUBSTANCE: disclosed is use of agonist Pear1 in preparing a drug for inhibiting fibroblast activation. Invention also discloses the Pear1 antibody and its antigen-binding fragment and their production and use. Disclosed is a method of screening a drug for inhibiting fibroblast activation.
EFFECT: inventions provide an anti-fibrous effect of activating Pear1 fibroblasts using Pear1 agonists and, in particular, an antibody targeting Pear1, inhibiting the ability of fibroblasts to synthesize an extracellular matrix, have wide application potential in treating fibrosing diseases and accompanying severe diseases.
27 cl, 8 dwg, 7 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| ANTIBODIES AGAINST CXCR2 AND THEIR USE | 2019 |
|
RU2807067C2 |
| ELEMENTS THAT BIND TO IL-1 BETA | 2013 |
|
RU2711118C2 |
| MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING SUBSTITUTE FUNCTIONAL ACTIVITY OF BLOOD COAGULATING FACTOR VIII CO-FACTOR, AND PHARMACEUTICAL COMPOSITION CONTAINING SPECIFIED MOLECULE AS ACTIVE INGREDIENT | 2018 |
|
RU2812909C2 |
| COMPOSITION FOR PREVENTION AND TREATMENT OF SKIN DISEASE CONTAINING SUBSTANCE SPECIFICALLY BINDING WITH VIMENTINE DERIVATIVE PEPTIDE | 2018 |
|
RU2751486C1 |
| ANTI-C10orf54 ANTIBODIES AND APPLICATIONS THEREOF | 2015 |
|
RU2819627C1 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| ANTIBODIES AGAINST PD-L1 AND THEIR OPTIONS | 2017 |
|
RU2770590C2 |
| TREATMENT OF HEADACHE WITH EXCESSIVE USE OF DRUGS WITH ANTIBODIES TO CGRP OR CGRP-R | 2020 |
|
RU2826186C2 |
